These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 2460018

  • 1. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M.
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [Abstract] [Full Text] [Related]

  • 2. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S, Akakura K, Shimazaki J.
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [Abstract] [Full Text] [Related]

  • 3. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J, de Torres Mateos JA.
    Arch Esp Urol; 1989 Aug; 42 Suppl 2():124-30. PubMed ID: 2484148
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E.
    N Engl J Med; 1987 Oct 08; 317(15):909-16. PubMed ID: 2442609
    [Abstract] [Full Text] [Related]

  • 5. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM, Bogdanowicz JF, Oosterom R, Schröder FH.
    Ned Tijdschr Geneeskd; 1990 Aug 18; 134(33):1596-600. PubMed ID: 1697651
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF, Bentvelsen FM, Oosterom R, Schroeder FH.
    Scand J Urol Nephrol Suppl; 1991 Aug 18; 138():97-103. PubMed ID: 1723815
    [Abstract] [Full Text] [Related]

  • 7. [Clinical study of tumor markers in prostatic cancer].
    Ishihara Y, Fukagai T, Ohta K, Hiromoto Y, Hiramori M, Torii T, Higaki Y, Imamura K.
    Hinyokika Kiyo; 1990 Apr 18; 36(4):425-31. PubMed ID: 1696063
    [Abstract] [Full Text] [Related]

  • 8. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
    Mortarelli EA.
    Ann Clin Lab Sci; 1992 Apr 18; 22(4):201-6. PubMed ID: 1380223
    [Abstract] [Full Text] [Related]

  • 9. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M.
    Anticancer Res; 1993 Apr 18; 13(3):769-77. PubMed ID: 7686362
    [Abstract] [Full Text] [Related]

  • 10. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A, Yoshida A, Kanda T, Sugihara S, Suzuki T, Tamura J, Kobayashi I, Nakazato Y.
    J Med; 2000 Apr 18; 31(1-2):101-10. PubMed ID: 10998759
    [Abstract] [Full Text] [Related]

  • 11. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
    Shinoda I.
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov 20; 25(11):2627-39. PubMed ID: 1703555
    [Abstract] [Full Text] [Related]

  • 12. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
    Moul JW, Connelly RR, Perahia B, McLeod DG.
    J Urol; 1998 Mar 20; 159(3):935-40. PubMed ID: 9474187
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
    Barak M, Mecz Y, Lurie A, Gruener N.
    J Lab Clin Med; 1989 May 20; 113(5):598-603. PubMed ID: 2469756
    [Abstract] [Full Text] [Related]

  • 14. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M, Kovacić K, Kastelan M.
    Anticancer Res; 1993 May 20; 13(1):215-8. PubMed ID: 7682800
    [Abstract] [Full Text] [Related]

  • 15. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct 20; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 16. Carcinoma of the prostate. Serum tumour markers.
    Ekman P.
    Scand J Urol Nephrol Suppl; 1991 Oct 20; 139():15-8. PubMed ID: 1722588
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F, Zambolin T, Bonora R, Panteghini M.
    J Nucl Med Allied Sci; 1990 Oct 20; 34(4 Suppl):85-7. PubMed ID: 1709211
    [Abstract] [Full Text] [Related]

  • 18. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.
    Scand J Urol Nephrol Suppl; 1994 Oct 20; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [Abstract] [Full Text] [Related]

  • 19. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 Oct 20; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 20. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
    Kabalin JN.
    Geriatrics; 1992 Sep 20; 47(9):26-32. PubMed ID: 1380941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.